ADMA Biologics, Inc. (ADMA)
13.67
+0.43
(+3.25%)
USD |
NASDAQ |
Nov 13, 16:00
13.67
0.00 (0.00%)
After-Hours: 19:59
ADMA Biologics Enterprise Value : 3.028B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 3.028B |
| November 11, 2026 | 3.017B |
| November 10, 2026 | 2.901B |
| November 09, 2026 | 2.928B |
| November 06, 2026 | 2.914B |
| November 05, 2026 | 3.021B |
| November 04, 2026 | 2.413B |
| November 03, 2026 | 2.553B |
| November 02, 2026 | 2.542B |
| October 30, 2026 | 2.620B |
| October 29, 2026 | 2.696B |
| October 28, 2026 | 2.591B |
| October 27, 2026 | 2.567B |
| October 26, 2026 | 2.543B |
| October 23, 2026 | 2.458B |
| October 22, 2026 | 2.518B |
| October 21, 2026 | 2.531B |
| October 20, 2026 | 2.580B |
| October 19, 2026 | 2.545B |
| October 16, 2026 | 2.458B |
| October 15, 2026 | 2.469B |
| October 14, 2026 | 2.382B |
| October 13, 2026 | 2.375B |
| October 12, 2026 | 2.346B |
| October 09, 2026 | 2.386B |
| Date | Value |
|---|---|
| October 08, 2026 | 2.380B |
| October 07, 2026 | 2.337B |
| October 06, 2026 | 2.346B |
| October 05, 2026 | 2.331B |
| October 02, 2026 | 2.244B |
| October 01, 2026 | 2.291B |
| September 30, 2026 | 2.313B |
| September 29, 2026 | 2.312B |
| September 28, 2026 | 2.348B |
| September 25, 2026 | 2.182B |
| September 24, 2026 | 2.213B |
| September 23, 2026 | 2.254B |
| September 22, 2026 | 2.279B |
| September 21, 2026 | 2.210B |
| September 18, 2026 | 2.121B |
| September 17, 2026 | 2.085B |
| September 16, 2026 | 2.073B |
| September 15, 2026 | 2.008B |
| September 14, 2026 | 2.128B |
| September 11, 2026 | 2.148B |
| September 10, 2026 | 2.184B |
| September 09, 2026 | 2.197B |
| September 08, 2026 | 2.218B |
| September 04, 2026 | 2.236B |
| September 03, 2026 | 2.227B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.230B |
| BioMarin Pharmaceutical, Inc. | 14.45B |
| Nektar Therapeutics | 722.92M |
| Rhythm Pharmaceuticals, Inc. | 7.514B |
| Arcutis Biotherapeutics, Inc. | 3.333B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 49.88M |
| Revenue (Quarterly) | 141.10M |
| Total Expenses (Quarterly) | 91.22M |
| EPS Diluted (Quarterly) | 0.2209 |
| Gross Profit Margin (Quarterly) | 70.77% |
| Profit Margin (Quarterly) | 35.35% |
| Earnings Yield | 5.68% |
| Operating Earnings Yield | 7.26% |
| Normalized Earnings Yield | 5.680 |